BioHarvest Sciences to Present at Sidoti Small-Cap Virtual Investor Conference on June 13, 2024

June 12, 2024

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – June 12, 2024) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the Sidoti Small-Cap Investor Conference, being held June 12-13, 2024.

CEO Ilan Sobel is scheduled to host virtual one-on-one meetings with institutional investors throughout the event, and will host a virtual presentation as follows:

Sidoti Small-Cap Conference
Date: Thursday, June 13, 2024
Time: 11:30 a.m. Eastern time
Webcast: https://sidoti.zoom.us/webinar/register/WN_-SfLHnO6QNyCoc-4J3FMDQ

All interested media and investors are invited to join this online presentation. Please join at least five minutes before the start of the presentation to ensure timely participation.

A live audio webcast and archive of the presentation will be available using the webcast link above. Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at BHSC@mzgroup.us.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology process to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
(604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
BHSC@mzgroup.us

Our Blog

2024 CEO Letter to Shareholders

“Our goal is to accelerate the Botanical Synthesis movement that our team has wholly dedicated themselves to – driving forward innovation, our...

Read More

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals – nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API’s) that focus on specific medical indications.

ABOUT BIOHARVEST SCIENCES INC.